SR-15099

SR-15099
Clinical data
Other namesSR15099; SR-15; SR15; SR 2.0; 5,6-Dichlorodesmethylbrorphine; 5,6-Dichloro-desmethylbrorphine
Drug classμ-Opioid receptor partial agonist; μ-Opioid receptor positive allosteric modulator; Analgesic
ATC code
  • None
Identifiers
  • 3-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H18BrCl2N3O
Molar mass455.18 g·mol−1
3D model (JSmol)
  • C1CN(CCC1N2C3=CC(=C(C=C3NC2=O)Cl)Cl)CC4=CC=C(C=C4)Br
  • InChI=1S/C19H18BrCl2N3O/c20-13-3-1-12(2-4-13)11-24-7-5-14(6-8-24)25-18-10-16(22)15(21)9-17(18)23-19(25)26/h1-4,9-10,14H,5-8,11H2,(H,23,26)
  • Key:MKPRNBUMJPGQCS-UHFFFAOYSA-N

SR-15099, also known as SR 2.0, is an atypical opioid and close analogue of SR-17018 and brorphine. It is the analogue of SR-17018 in which the chlorine atom on the benzyl ring has been replaced with a bromine atom. The drug is a non-competitive partial biased agonist of the μ-opioid receptor (MOR) similarly to SR-17018. It has similar effects in animals as SR-17018, such as having robust analgesic effects but producing minimal respiratory depression or hyperlocomotion. SR-15099 was first described in the scientific literature by Laura M. Bohn and colleagues by 2017. Like SR-17018 rather than being used recreationally itself, SR-15099 is typically employed by users to prevent opioid withdrawal symptoms and facilitate opioid discontinuation in the context of opioid dependence.

See also

References

  1. 1 2 3 4 Acevedo-Canabal A, Grim TW, Schmid CL, McFague N, Stahl EL, Kennedy NM, et al. (June 2023). "Hyperactivity in Mice Induced by Opioid Agonists with Partial Intrinsic Efficacy and Biased Agonism Administered Alone and in Combination with Morphine". Biomolecules. 13 (6): 935. doi:10.3390/biom13060935. PMC 10295947. PMID 37371516.
  2. 1 2 3 4 5 Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, et al. (November 2017). "Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics". Cell. 171 (5): 1165–1175.e13. doi:10.1016/j.cell.2017.10.035. PMC 5731250. PMID 29149605.
  3. ↑ Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, et al. (April 2021). "DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles". ACS Chemical Neuroscience. 12 (7): 1072–1092. doi:10.1021/acschemneuro.1c00037. PMID 33760580.
  4. ↑ Azevedo Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C, Calò G (August 2020). "Biased versus Partial Agonism in the Search for Safer Opioid Analgesics". Molecules. 25 (17). Basel, Switzerland: 3870. doi:10.3390/molecules25173870. PMC 7504468. PMID 32854452.